Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The motion sickness drugs market was valued at USD 1.26 Billion in 2025. It is poised to grow at a CAGR of 4.80% during the forecast period of 2026-2035, and reach USD 2.01 Billion by 2035. The market growth is driven by the post-pandemic rebound in travel and a rising preference for over-the-counter antihistamines for travel-related nausea management.
Latest News on the Motion Sickness Drugs Market (2026)
April 2026: Vanda Advances Phase III Plans for Tradipitant in GLP-1 Nausea
According to American Council on Science and Health, Vanda Pharmaceuticals continued advancing its Phase III program in early 2026 for tradipitant in GLP-1-induced nausea, building on the December 2025 FDA approval of Nereus for motion sickness, the first new clearance in over 40 years. The NK-1 receptor antagonist is positioned to expand beyond the traditional anticholinergic and antihistamine therapeutic landscape.
March 2026: Tradipitant Reshapes Treatment Landscape Beyond Scopolamine, Meclizine
As reported by Straight Healthcare, the February 25, 2026 clinical analysis confirmed tradipitant's differentiated mechanism, working via NK-1 receptor antagonism rather than the sedating anticholinergic pathways of scopolamine patches and over-the-counter meclizine or dimenhydrinate. Phase 3 boat studies showed approximately 50% vomiting reduction versus placebo, signaling a potential premium-priced segment within the historically generic motion sickness drug market.
Key Market Trends and Insights
- By treatment type, antihistamines are expected to dominate the market with around 46% share in the forecast period.
- Based on the dosage form, oral formulations are expected to lead the market in the forecast period.
- By distribution channel, retail pharmacies are expected to dominate the market in the forecast period.
Market Size & Forecast
- Market Size in 2025: USD 1.26 Billion
- Projected Market Size in 2035: USD 2.01 Billion
- Compound Annual Growth Rate (CAGR) of 2026 to 2035: 4.80%
Compound Annual Growth Rate
4.8%
Value in USD Billion
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Motion Sickness Drugs Market Overview
Motion sickness drugs are pharmacological agents used to prevent or relieve nausea, dizziness, and vomiting caused by sensory mismatch during travel by car, boat, plane, or virtual environments. The market was valued at USD 1.26 Billion in 2025 and is poised to grow at a CAGR of 4.80%. The market demonstrates steady expansion driven by rising travel activity, increasing over-the-counter adoption, and growing preference for convenient formulations. The demand is further supported by stronger pharmacy access, innovation in antihistamine-based therapies, and expanding consumer awareness of motion-related discomfort management across major healthcare systems.
Motion Sickness Drugs Market Growth Drivers
Rising Motion Sickness Prevalence Among Young Adults Supporting Market Expansion
Increasing prevalence of motion sickness among young adults is significantly contributing to the expansion of the motion sickness drugs market across eight major markets. The demand is being driven by higher travel frequency and heightened susceptibility to motion-related discomfort in active populations. According to Dwivedi et al., 2024, a study involving 562 participants aged 18 to 28 years reported that 71.4% experienced mild symptoms, while 27.8% experienced moderate symptoms, indicating a high overall prevalence. The findings emphasize the impact on quality of life and productivity, reinforcing the need for effective therapeutic and preventive pharmaceutical interventions across healthcare systems.
Motion Sickness Drugs Market Trends
Some of the notable trends in the market are rising OTC adoption and increasing introduction of novel receptor-targeted therapies.
NK1 Receptor Antagonist Innovation is Likely to Enhance Market Growth
The market is witnessing a shift toward novel neurokinin-1 receptor antagonist therapies, supported by advancements in targeted antiemetic mechanisms. For instance, in May 2026, Vanda Pharmaceuticals Inc. announced the U.S. commercial availability of NEREUS™ (tradipitant), the first new pharmacologic treatment for motion sickness in over 40 years. This innovation reflects growing demand for more effective, non-traditional therapies beyond antihistamines and anticholinergics. The introduction of targeted NK1 receptor blockade improves treatment outcomes and expands therapeutic options, thereby strengthening clinical adoption and enhancing overall market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Motion Sickness Drugs Market Segmentation
Market Breakup by Treatment Type
- Anticholinergics
- First-Generation Antihistamines
- Second-Generation / Non-Sedating Antihistamines
- Neurokinin-1 (NK1) Receptor Antagonists
- Herbal & Nutraceuticals
- Neuromodulation & Wearable Devices
- Others
Market Breakup by Dosage Form
- Oral
- Transdermal
- Nasal Sprays & Gels
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Market Breakup by Country
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Motion Sickness Drugs Market Share
Antihistamines Lead the Market Segmentation by Treatment Type
The market includes various anticholinergics, first-generation antihistamines, second-generation/non-sedating antihistamines, neurokinin-1 (NK1) receptor antagonists, herbal & nutraceuticals, neuromodulation & wearable devices, and others. Among these, first-generation antihistamines are expected to lead the market due to their widespread over-the-counter availability, strong efficacy, and cost-effectiveness. The growth is further supported by rising travel demand and consumer preference for easily accessible therapies. OTC brands expanded chewable and non-drowsy formulations, strengthening demand. This ongoing trend reinforces their dominant position in the market.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Motion Sickness Drugs Market Analysis by Region
Among all the regions, the United States is expected to lead the motion sickness drugs market due to strong regulatory support, high travel-related demand, and early adoption of advanced therapies. For instance, in December 2025, Vanda Pharmaceuticals announced U.S. Food and Drug Administration approval of NEREUS (tradipitant), the first new pharmacologic treatment for motion sickness in over four decades, as reported by PR Newswire. This milestone reinforces the region’s leadership in innovation and accelerates clinical and commercial advancement in motion sickness management.
Leading Players in the Motion Sickness Drugs Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. is a leading OTC healthcare company best known for its motion sickness brand Dramamine®, which is widely used for the prevention and treatment of nausea and dizziness during travel. The company has recently expanded its product line with Dramamine Advanced Herbals, strengthening its position in the market. Its strong retail presence and pharmacist-recommended products support growing demand across travel-related care solutions.
Perrigo Company plc
Perrigo Company plc is a global self-care pharmaceutical company with a strong OTC and generic portfolio, including scopolamine transdermal systems for motion sickness and nausea prevention. The company recently launched an AB-rated generic version of Transderm Scop®, enhancing affordable access to anticholinergic therapy. Perrigo plays a key role in expanding cost-effective motion sickness treatment options through its broad retail and prescription distribution network.
Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in developing and commercializing a wide range of therapeutic solutions, including supportive care and anti-nausea treatments relevant to motion sickness management. The company leverages its strong R&D capabilities and global reach to contribute indirectly to nausea and dizziness-related therapies, supporting innovation in central nervous system and travel-related care segments in the motion sickness drugs market.
Lupin Limited
Lupin Limited is a multinational pharmaceutical company specializing in generics and specialty medicines, with involvement in motion sickness treatment through meclizine hydrochloride tablets used for nausea, vomiting, and dizziness control. The company recently received FDA approval for its generic Antivert equivalent, strengthening its presence in the market. Lupin continues to expand affordable CNS-related therapies across global regulated and emerging markets.
Other key players in the market are Caleb Pharmaceuticals, Inc., Myungmoon Pharm Co., Ltd., Vanda Pharmaceuticals Inc., Baxter International Inc., Church & Dwight Co., Inc., and WellSpring Pharmaceutical Corporation.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Key Questions Answered in the Motion Sickness Drugs Market Report
- What was the motion sickness drugs market value in 2025?
- What is the motion sickness drugs market forecast outlook for 2026-2035?
- What major factors aid the demand for the motion sickness drugs market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major motion sickness drugs market trends?
- Which treatment type is expected to dominate the market segment?
- Which dosage form is anticipated to lead the motion sickness drugs market?
- Which distribution channel is expected to lead the motion sickness drugs market?
- Who are the key players in the motion sickness drugs market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$5499 $4949
-
$3299 $2969
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Key Questions Answered in the Report
The global motion sickness drugs market is projected to grow at a CAGR of 4.80% between 2026 and 2035.
The major drivers of the industry, such as the growing sales of generic drugs, particularly OTC (over the counter) drugs, increasing population, increasing health awareness, and the growing research and development activities, are expected to aid the market growth.
Advancements in nauseogenic information technology is the key market trend guiding the growth of the industry.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Anticholinergics and antihistamines are the leading products of motion sickness drugs in the market.
The major players in the industry are Baxter International Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Pfizer Inc., and Prestige Consumer Healthcare Inc., among others.
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Dosage Form |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
